Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | PDIA6 | Q15084 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22219023 | 0.95 | SMN1; SMN2 (0.48) | SMN1; SMN2MEN1KMT2APDIA6LMNA | |
| SCHEMBL25405576 | 0.86 | PDIA6 (0.51) | SMN1; SMN2MEN1KMT2APDIA6LMNA | |
| SCHEMBL17669368 | 0.85 | MAOA (0.41) | SMN1; SMN2MEN1KMT2APDIA6LMNA | |
| SCHEMBL25407032 | 0.85 | PDIA6 (0.54) | SMN1; SMN2MEN1KMT2APDIA6LMNA | |
| SCHEMBL25406440 | 0.85 | PDIA6 (0.54) | SMN1; SMN2MEN1KMT2APDIA6LMNA | |
| SCHEMBL25261232 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2APDIA6LMNA | |
| SCHEMBL1527596 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1KMT2APDIA6LMNA | |
| SCHEMBL6503962 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2APDIA6LMNA | |
| SCHEMBL9931333 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1KMT2APDIA6LMNA | |
| SCHEMBL8256675 | 0.82 | HPGD (0.55) | SMN1; SMN2MEN1KMT2APDIA6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-26 | — | — | US | disclosed |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-05 | — | — | US | disclosed |
| US-10131648-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-20 | — | — | US | disclosed |
| US-10106553-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-23 | — | — | US | disclosed |
| US-20170362196-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-21 | — | — | US | disclosed |
| WO-2017180457-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017180571-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-19 | — | — | WO | disclosed |
| US-9790198-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-17 | — | — | US | disclosed |
| US-20170290800-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | disclosed |
| US-20170291908-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-10-12 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7977387-B2 | Aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2011-07-12 | — | — | US | disclosed |
| US-20110098298-A1 | New Pyridin-3-Amine Derivatives | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-04-28 | — | — | US | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
| CN-101395136-A | New pyridin-3-amine derivatives | ALMIRALL LAB (ES) | 2009-03-25 | — | — | CN | disclosed |
| EP-1987005-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007096072-A2 | NEW PYRIDIN-3-AMINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2007-08-30 | — | — | WO | disclosed |
| US-20060166990-A1 | Novel aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| EP-1658263-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | Leo Pharma A/S (DK) | 2006-05-24 | — | — | EP | disclosed |
| WO-2005009940-A1 | NOVEL AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290800-A1 | GPR40 AGONISTS IN ANTI-DIABETIC DRUG COMBINATIONS | GPR119, GLP1R, GPR65 | SMN1; SMN2 4828/4885MEN1 4490/4885KMT2A 2049/4885 |
| US-20170291908-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | SMN1; SMN2 3726/4885MEN1 4111/4885KMT2A 3251/4885 |
| US-10195178-B2 | GPR40 agonists in anti-diabetic drug combinations | GPR119, GLP1R, GPR65 | SMN1; SMN2 4828/4885MEN1 4490/4885KMT2A 2049/4885 |
| US-20060166990-A1 | Novel aminobenzophenone compounds | NFKBIA, UACA, ALDH7A1 | SMN1; SMN2 4625/4885MEN1 1114/4885KMT2A 3430/4885 |
| US-20170362196-A1 | SUBSTITUTED BENZOTHIOPHENYL DERIVATIVES AS GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR52, GPR65 | SMN1; SMN2 4392/4885MEN1 4369/4885KMT2A 2973/4885 |
| US-20110098298-A1 | New Pyridin-3-Amine Derivatives | MAPK1, MAP4K2, MAPK3 | SMN1; SMN2 1571/4885MEN1 3190/4885KMT2A 2699/4885 |
| US-10662170-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR52, GPR65 | SMN1; SMN2 4392/4885MEN1 4369/4885KMT2A 2973/4885 |
| US-10106553-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR52 | SMN1; SMN2 3726/4885MEN1 4111/4885KMT2A 3251/4885 |
| US-10131648-B2 | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes | GPR119, GPR52, GPR65 | SMN1; SMN2 4392/4885MEN1 4369/4885KMT2A 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.